Loading company…
Monopteros Therapeutics develops therapies that reprogram regulatory T cells for cancer immunotherapy.
Founded in 2019, Monopteros Therapeutics is a pharmaceutical research company developing treatments that reprogram regulatory T cells for cancer immunotherapy resistance. Co-founders are Thorsten Mempel, MD, Ph.D., and Ulrich von Andrian, MD. In 2021, the company raised USD 20 million in Series A funding from Medicxi. Its MPT-0118 tablet is being studied in a Phase 1/1b clinical trial.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in